Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

by Anderson, L.D., Jr, Beksac, M., Corso, A., Dimopoulos, M., Dürig, J., Engelhardt, M., Galli, M., Grote, L., Jenner, M., Jiang, R., Kanate, A.S, Larocca, A., Liberati, A.M, Lindsay, J., Moreau, P., Oriol, A., Pavic, M., Peluso, T., Richardson, P.G, Robak, P., Rodriguez-Otero, P., Salomo, M., Schjesvold, F., Sonneveld, P., Vural, F., Weisel, K., White, D., Yagci, M.
Published 2022